ATNF Stock Overview
A clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
180 Life Sciences Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.22 |
| 52 Week High | US$17.75 |
| 52 Week Low | US$1.16 |
| Beta | 0.25 |
| 11 Month Change | -47.89% |
| 3 Month Change | 16.23% |
| 1 Year Change | -62.66% |
| 33 Year Change | -99.90% |
| 5 Year Change | -99.94% |
| Change since IPO | -99.94% |
Recent News & Updates
Recent updates
180 Life Sciences to raise $6.5M in direct stock offering
Jul 18180 Life Sciences: Looking At Inflammation With Cannabis (Podcast)
Sep 08What Type Of Shareholders Make Up 180 Life Sciences Corp.'s (NASDAQ:ATNF) Share Registry?
Feb 17
SPAC biotech 180 Life Sciences to ring Nasdaq opening bell today
Nov 27Shareholder Returns
| ATNF | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.9% | 4.0% | 2.2% |
| 1Y | -62.7% | 18.3% | 32.6% |
Return vs Industry: ATNF underperformed the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: ATNF underperformed the US Market which returned 31.6% over the past year.
Price Volatility
| ATNF volatility | |
|---|---|
| ATNF Average Weekly Movement | 93.3% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ATNF's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ATNF's weekly volatility has increased from 51% to 93% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 4 | Lloyd Jordan | 180lifesciences.com |
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren’s Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Palo Alto, California.
180 Life Sciences Corp. Fundamentals Summary
| ATNF fundamental statistics | |
|---|---|
| Market cap | US$2.31m |
| Earnings (TTM) | -US$3.12m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs ATNF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATNF income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$3.12m |
| Earnings | -US$3.12m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.04 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 13.0% |
How did ATNF perform over the long term?
See historical performance and comparison